Continued epidemic of bladder cancer in workers exposed to ortho-toluidine in a chemical factory.

J Occup Environ Med

Center for the Biology of Natural Systems, Queens College, City University of New York, NY, USA.

Published: February 2004

Ortho-toluidine (o-toluidine), an aromatic amine, is classified by the International Agency for Research on Cancer as a probable human carcinogen. A cohort study published in 1991 reported a 6.5-fold excess incidence of bladder cancer in a chemical plant that used o-toluidine. We report 19 additional cases of bladder cancer among workers in this cohort, yielding a total of 34 cases of bladder cancer in the cohort to date. The number of bladder cancers diagnosed in the recent period has increased. The timing of onset of exposure to o-toluidine of numerous cases of bladder cancer after 1968, and especially 1975, suggests that potentially confounding occupational exposures other than o-toluidine were not responsible for the observed excess bladder cancer. A formal cohort update is strongly indicated. This study further supports the human bladder carcinogenicity of o-toluidine.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.jom.0000111602.76443.15DOI Listing

Publication Analysis

Top Keywords

bladder cancer
24
cases bladder
12
bladder
8
cancer workers
8
cancer
7
o-toluidine
5
continued epidemic
4
epidemic bladder
4
workers exposed
4
exposed ortho-toluidine
4

Similar Publications

Purpose: Locally advanced colorectal tumors frequently invade adjacent organs, particularly the urinary bladder in the sigmoid colon and upper rectum, complicating multivisceral resections. This study compared postoperative outcomes of partial cystectomy (PC) and total cystectomy (TC) in patients with locally advanced colorectal cancer.

Methods: A systematic review was conducted in PubMed, Scopus, Central Register of Clinical Trials, and Web of Science for studies published up to November 2024.

View Article and Find Full Text PDF

Limited treatment options are available for bladder cancer (BCa) resulting in extremely high mortality rates. Cyclovirobuxine D (CVB-D), a naturally alkaloid, reportedly exhibits notable antitumor activity against diverse tumor types. However, its impact on CVB-D on BCa and its precise molecular targets remain unexplored.

View Article and Find Full Text PDF

Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.

BJU Int

January 2025

Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy.

Objective: To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high-risk and very-high-risk non-muscle-invasive bladder cancer (NMIBC) after previous Bacillus Calmette-Guérin (BCG) treatment.

Materials And Methods: Data were retrospectively collected from 95 patients with NMIBC, treated with Gem/Doce at 12 European centres between 2021 and 2024. Patients previously treated with BCG who had completed a full induction course and received at least one follow-up evaluation were included.

View Article and Find Full Text PDF

Previous epidemiological studies have shown that diabetes is associated with an increased risk of several cancers, including bladder cancer. However, prediction models for bladder cancer among diabetes patients remain scarce. This study aims to develop a scoring system for bladder cancer risk prediction among diabetes patients who receive routine care in general outpatient clinics using a machine learning-guided approach.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!